Meeting
2022 ASCO Annual Meeting
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Authors
Andrea Grace Bocobo
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Andrea Grace Bocobo , Renee Wang , Spencer Behr , Julia C. Carnevale , Pelin Cinar , Eric Andrew Collisson , Lawrence Fong , Bridget P Keenan , Wesley Allen Kidder , Andrew H. Ko , Kanti Pallav Kolli , Megan Kennedy , Angela Laffan , Sorbarikor Piawah , Marin Pollak , Gabriel Schwartz , Julia Whitman , Li Zhang , Katherine Van Loon , Chloe Evelyn Atreya
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03396926
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3565)
DOI
10.1200/JCO.2022.40.16_suppl.3565
Abstract #
3565
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
First Author: Andrea Grace Bocobo
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellite-stable, refractory, metastatic colorectal cancer (mCRC).
First Author: Tyler Friedrich